Study S001101

An Open-label, One-sequence Cross-over, Single Centre Trial Investigating the Influence of Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug After Multiple Dose Administration of Semaglutide in Subjects With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT01324505
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 43
Start: 2011-03
Primary completion: 2012-01
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:semaglutide; DRUG:placebo; DRUG:Microgyn®
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1119-2214; EUDRACT_NUMBER:2010-022435-11

Registered primary outcomes

Area under the ethinylestradiol concentration-time curve [in the 24 hour dosing interval]
Area under the levonorgestrel concentration-time curve [in the 24 hour dosing interval]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.